Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, a critical component of genetic regulation. The company's primary mission is to leverage its expertise in microRNA biology to treat diseases with significant unmet medical needs. Regulus Therapeutics operates in the health care sector, with a particular emphasis on conditions like genetic and fibrotic diseases. By exploring the regulatory role of microRNAs, the company aims to develop regenerating therapies that modify disease progression with a high specificity.

The company plays a crucial role in advancing the understanding of microRNA-based therapies, which hold the potential to transform how challenging diseases are managed. Regulus’s endeavors support broader industry efforts to harness novel biological mechanisms for therapeutic innovation, making it a notable player in the biotechnology field. Founded with a vision to target complex pathologies through microRNA modulation, Regulus Therapeutics continues to engage in clinical trials and collaborative partnerships to expand its scientific and therapeutic horizons, thus contributing significantly to the future prospects of personalized medicine and targeted treatment strategies.